Shares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have been given a consensus recommendation of "Buy" by the twelve analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $47.25.
A number of equities analysts recently commented on the company. Wedbush initiated coverage on Immunic in a report on Monday. They set an "outperform" rating and a $45.00 price target for the company. Wolfe Research assumed coverage on shares of Immunic in a report on Friday, May 22nd. They issued an "outperform" rating for the company. Roth Capital reissued a "buy" rating and set a $19.00 target price on shares of Immunic in a report on Thursday, May 14th. HC Wainwright restated a "buy" rating and set a $22.00 price objective (up from $5.00) on shares of Immunic in a research report on Thursday, April 30th. Finally, Wall Street Zen raised shares of Immunic from a "sell" rating to a "hold" rating in a report on Saturday, August 15th.
Check Out Our Latest Stock Report on Immunic
Institutional Trading of Immunic
A number of hedge funds have recently added to or reduced their stakes in IMUX. Jane Street Group LLC lifted its stake in shares of Immunic by 279.3% in the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock valued at $226,000 after acquiring an additional 152,726 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Immunic by 5.3% during the third quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company's stock valued at $3,832,000 after purchasing an additional 219,957 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Immunic during the third quarter worth about $239,000. Two Sigma Investments LP acquired a new position in shares of Immunic in the third quarter valued at approximately $52,000. Finally, Virtu Financial LLC bought a new position in Immunic in the 3rd quarter valued at approximately $99,000. Institutional investors and hedge funds own 51.82% of the company's stock.
Immunic Trading Down 2.7%
Shares of IMUX stock opened at $16.45 on Thursday. The firm's fifty day moving average price is $14.72 and its two-hundred day moving average price is $12.31. The firm has a market capitalization of $224.38 million, a P/E ratio of -3.76 and a beta of 1.41. Immunic has a 1 year low of $5.06 and a 1 year high of $17.43.
Immunic (NASDAQ:IMUX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.36. As a group, equities research analysts forecast that Immunic will post -3.88 EPS for the current fiscal year.
Immunic Company Profile
(
Get Free Report)
Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company's research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.
Immunic's lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn's disease and relapsing multiple sclerosis.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
